0001209191-19-007770.txt : 20190206 0001209191-19-007770.hdr.sgml : 20190206 20190206164936 ACCESSION NUMBER: 0001209191-19-007770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190204 FILED AS OF DATE: 20190206 DATE AS OF CHANGE: 20190206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silva Paul M CENTRAL INDEX KEY: 0001446372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 19572071 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-04 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001446372 Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP & Interim CFO Common Stock 2019-02-04 4 M 0 809 86.52 A 16896 D Common Stock 2019-02-04 4 S 0 809 189.19 D 16087 D Common Stock 2019-02-04 4 S 0 600 185.11 D 15487 D Common Stock 2019-02-04 4 S 0 450 186.17 D 15037 D Common Stock 2019-02-04 4 S 0 2268 186.85 D 12769 D Common Stock 2019-02-04 4 S 0 120 188.33 D 12649 D Stock Option (Right to Buy) 86.52 2019-02-04 4 M 0 809 0.00 D 2027-02-02 Common Stock 809 6472 D Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $185.11 (range $184.54 to $185.49). Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $186.17 (range $185.74 to $186.52). Open market sales reported on this line occurred at a weighted average price of $186.85 (range $186.62 to $187.33). Open market sales reported on this line occurred at a weighted average price of $188.33 (range $188.25 to $188.35). The option vests in 16 quarterly installments from 02/03/2017. /s/ Omar White, Attorney-in-Fact 2019-02-06